Pharma Mar, S.A. (BME:PHM)
66.60
-0.65 (-0.97%)
Nov 16, 2026, 5:35 PM CET
Pharma Mar Revenue
Pharma Mar had revenue of 54.42M EUR in the quarter ending September 30, 2026, with 40.04% growth. This brings the company's total for the last twelve months to 237.40M, up 25.43% year-over-year. In the year 2025, Pharma Mar had annual revenue of 221.39M with 26.61% growth. That makes Pharma Mar the 15,550th largest company in the world by revenue and 88th in Spain.
Revenue (ttm)
237.40M
Revenue Growth
+25.43%
P/S Ratio
4.86
Revenue / Employee
470.09K
Employees
505
Market Cap
1.15B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Pharma Mar breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 221.39M | 46.54M | 26.61% |
| Dec 31, 2024 | 174.86M | 16.70M | 10.56% |
| Dec 31, 2023 | 158.15M | -38.19M | -19.45% |
| Dec 31, 2022 | 196.34M | -33.49M | -14.57% |
| Dec 31, 2021 | 229.83M | -40.13M | -14.87% |
| Dec 31, 2020 | 269.96M | 184.14M | 214.57% |
| Dec 31, 2019 | 85.82M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.60B |
| Almirall | 1.18B |
| Laboratorios Farmaceuticos Rovi | 828.59M |
| Faes Farma | 736.53M |
| Laboratorio Reig Jofre | 330.04M |
| Clínica Baviera | 320.67M |
| Prim, S.A. | 250.65M |
| Atrys Health | 147.68M |
Pharma Mar News
- 18 days ago - Pharma Mar Earnings release: Q3 2026 - Filings
- 18 days ago - Pharma Mar Quarterly report: Q3 2026 - Filings
- 27 days ago - Pharma Mar Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 3 months ago - Pharma Mar Slides: Corporate presentation - Filings
- 3 months ago - Pharma Mar Earnings Call Transcript: Q2 2026 - Transcripts
- 3 months ago - Pharma Mar Earnings release: Q2 2026 - Filings
- 3 months ago - Pharma Mar Quarterly report: Q2 2026 - Filings
- 5 months ago - Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan - TheFly